The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.
 
Niels W.C.J. van de Donk
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Cellectis (Inst); Janssen (Inst)
 
Mounzer E. Agha
No Relationships to Disclose
 
Adam D. Cohen
Consulting or Advisory Role - AstraZeneca; Bristol Meyers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Novartis; Oncopeptides; Roche/Genentech; Seagen; Takeda
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patents related to CAR T cells and biomarkers of Cytokine Release Syndrome
Expert Testimony - Janssen Oncology
Travel, Accommodations, Expenses - Celgene; GlaxoSmithKline; Janssen Oncology; Janssen Oncology; Takeda
 
Yael C. Cohen
Honoraria - Amgen; GlaxoSmithKline; Janssen; Medison; Medison; NeoPharm; Takeda
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen; Medison
Research Funding - Amgen (Inst); Karyopharm Therapeutics (Inst); Takeda (Inst)
 
Sébastien Anguille
No Relationships to Disclose
 
Tessa Kerre
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Johnson & Johnson (Inst); MSD (Inst); Novartis (Inst)
 
Wilfried Roeloffzen
No Relationships to Disclose
 
Jordan Mark Schecter
Employment - Janssen Oncology
Stock and Other Ownership Interests - Janssen Oncology
 
Kevin C. De Braganca
Employment - Janssen Research & Development
 
Helen Varsos
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Pankaj Mistry
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Tito Roccia
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Enrique Zudaire
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
Patents, Royalties, Other Intellectual Property - Patents pending with Janssen
Travel, Accommodations, Expenses - Janssen Research & Development
 
Christina Corsale
Employment - Janssen
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Muhammad Akram
Employment - Legend Biotech
Stock and Other Ownership Interests - Legend Biotech
Honoraria - Legend Biotech
Travel, Accommodations, Expenses - Legend Biotech
 
Dong Geng
Employment - Legend Biotech
Stock and Other Ownership Interests - Legend Biotech
Travel, Accommodations, Expenses - Legend Biotech
 
Tonia Nesheiwat
Employment - Legend Biotech
Stock and Other Ownership Interests - Legend Biotech
 
Lida Bubuteishvili-Pacaud
Employment - Legend biotech
Stock and Other Ownership Interests - Legend Biotech
 
Pieter Sonneveld
Consulting or Advisory Role - Amgen; CARsgen Therapeutics; Celgene; Janssen; Karyopharm Therapeutics
Research Funding - Amgen (Inst); BMS (Inst); Janssen (Inst); Skyline Diagnostics (Inst)
 
Sonja Zweegman
Consulting or Advisory Role - Celgene (Inst); Janssen-Cilag (Inst); Oncopeptides (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Celgene (Inst); Janssen-Cilag (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Takeda